Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Presence of blood eosinophilia during NEC predicts life-threatening complications for preemies

Premature infants have heightened risks of deadly diseases because their organs and immune systems are not fully developed. Necrotizing enterocolitis (NEC), a major gastrointestinal disease that causes the intestines to die, is a leading cause of death among these infants and is the most the common disease for babies born before 32 weeks.

1 Oct 2015

Common IBD therapeutic target may protect against intestinal inflammation

Investigators at Children's Hospital Los Angeles have found that a common therapeutic target for the treatment of inflammatory bowel disease (IBD) may actually protect against intestinal inflammation by inhibiting pathogenic T-cells. This discovery, reported in the October 2015 issue of Gastroenterology, could lead to new treatment options for the 65 percent of individuals with IBD who do not respond or become resistant to anti-TNF medications.

26 Sep 2015

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.

25 Sep 2015

MIT researchers devise new system to genetically engineer viruses to combat harmful bacteria

In the hunt for new ways to kill harmful bacteria, scientists have turned to a natural predator: viruses that infect bacteria. By tweaking the genomes of these viruses, known as bacteriophages, researchers hope to customize them to target any type of pathogenic bacteria.

23 Sep 2015

Researchers use new software tool to identify genetic overlaps between palmitoleic acid and Crohn's disease

Some research has suggested that omega-3 fatty acids, abundant in fish oils, can relieve inflammation in Crohn's disease. But a new study using software developed by Duke scientists hints that we should be paying closer attention to what the other omegas -- namely, omega-6 and omega-7 -- are doing to improve or worsen the disease.

16 Sep 2015

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.

16 Sep 2015

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

The American Gastroenterological Association, in partnership with the Crohn's & Colitis Foundation of America and Janssen Biotech, Inc., announced today that Theresa Alenghat, VMD, PhD, from Cincinnati Children's Hospital Medical Center, OH, was awarded with the 2015 AGA-CCFA-Janssen Research Award in Inflammatory Bowel Disease (IBD) Epigenetics Research.

27 Aug 2015

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.

26 Aug 2015

Scientists bridge gap between two separate pieces of embryonic mouse intestine

University of Manchester scientists have bridged a gap between two separate pieces of small intestine kept alive outside the body, in an advance which could have implications for surgery in human adults and babies.

25 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax.

19 Aug 2015

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics, Inc. announces the launch of an observational clinical study in patients who contracted Progressive Multifocal Leukoencephalopathy (PML), the rare and often fatal brain infection that arises as an unintended side effect of some medications used for treatment of Multiple Sclerosis, Crohn's disease, Ulcerative Colitis and certain cancers of the blood and lymph.

13 Aug 2015

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

In a new study of more than 125,000 pregnant women in Sweden, researchers at the Sahlgrenska Academy found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

12 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

Adults exposed to childhood physical or sexual abuse at risk for ulcerative colitis

Adults who were exposed to childhood physical or sexual abuse were approximately twice as likely to have ulcerative colitis, according to a new nationally representative study from four researchers at the University of Toronto.

7 Aug 2015

Study uncovers role of intra-abdominal fat cells in development and progression of IBD

Intra-abdominal fat cells may contribute to the development and progression of inflammatory bowel disease (IBD), according to a study published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

6 Aug 2015

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Presence of blood eosinophilia during NEC predicts life-threatening complications for preemies

Common IBD therapeutic target may protect against intestinal inflammation

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

MIT researchers devise new system to genetically engineer viruses to combat harmful bacteria

Researchers use new software tool to identify genetic overlaps between palmitoleic acid and Crohn's disease

Immune Pharmaceuticals’ CEO establishes stock trading plan

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Scientists bridge gap between two separate pieces of embryonic mouse intestine

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Adults exposed to childhood physical or sexual abuse at risk for ulcerative colitis

Study uncovers role of intra-abdominal fat cells in development and progression of IBD

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in